The World of Biolog Gets Bigger! Biolog Adds Contract Services and New Analysis Software to Its Portfolio of Tools With the Acquisition of MIDI Labs and MIDI, Inc.
HAYWARD, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic profiling products, today announced the acquisition of MIDI Labs and MIDI, Inc., both headquartered in Newark, Delaware. Biolog and MIDI serve many of the same customers and industries. Over the last two decades, both companies have served the microbial ID community, offering complimentary products and services. The acquisition will be funded through an expansion of Biolog's Series A financing, led by BroadOak Capital and Research Corporation Technologies.
MIDI Labs, an innovator in microbial identification, currently offers contract laboratory services for microbial identification and enumeration to deliver critical, time-sensitive ID for pharmaceutical, probiotic, food and beverage, and personal care manufacturing operations using sequencing and MALDI-TOF mass spectrometry. MIDI, Inc., a pioneer of microbial identification by fatty acid analysis, offers its Sherlock software packages in various end-markets that enable soil community, spice, botanical, and dietary supplement analysis using GC, GC-MS and HPLC.
MIDI Labs will supplement its existing offerings with Biolog's OmniLog® platform for metabolic phenotypic analysis. "Combining the technologies from Biolog and MIDI will allow us to offer polyphasic analysis to customers doing any type of microbial ID or phenotypic metabolic profiling to enable a direct link between genotype, phenotype, and proteomics," said Robert Wicke, CEO of Biolog.
FDA registered, USDA permitted, and ISO 17025: 2017 accredited, MIDI Labs has set the standard in providing accurate and reliable services for 25+ years. "This is a big win for MIDI and our customers. Together with Biolog, we'll be able to identify tens of thousands of microbiota and add phenotypic services for customers needing a more complete picture of an organism's metabolic function," said Gary Jackoway, President of MIDI Labs.
This is Biolog's first acquisition under its new leadership team, which came on board in May 2022. "We are thrilled to welcome the MIDI team into the Biolog family. This acquisition enables rapid expansion of our ID database that will benefit all our ID customers, and with our combination of systems and services, can offer even more value to customers, regardless of scale or budget," said Wicke.
Biolog is a leader in phenotypic cell profiling, metabolic characterization, and microbial identification. Located in Hayward, CA, the company's products enable characterization of microbial cells, mammalian cells and mitochondria as well as identification of thousands of species of bacteria, yeast, and fungi. For more information, visit www.biolog.com.
John Proctor, Ph.D.
This content was issued through the press release distribution service at Newswire.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Coloplast Finance B.V. - Decisions at the Annual General Meeting31.1.2023 20:24:07 CET | Press release
Decisions at the Annual General Meeting On 31 January 2023, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S approved the annual report for the financial year 2021/22 (for the first 7-months from incorporation until 30 September 2022). Attachment 01_2023_Annual General Meeting_Coloplast Finance
Nokia Corporation: Repurchase of own shares on 31.01.202331.1.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 31 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 31.01.2023 Espoo, Finland – On 31 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL261,4854.33CEUX19,9384.34AQEU23,7644.33TQEX12,8134.34Total318,0004.33 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 20
GA-ASI's Eaglet Takes Its First Flight31.1.2023 19:00:00 CET | Press release
SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- General Atomics Aeronautical Systems, Inc. (GA-ASI) flew a new survivable Air-Launched Effect (ALE) for the first time as part of a flight demonstration based out of the Dugway Proving Grounds, Utah, on Dec. 8, 2022. The ALE, known as Eaglet, was launched from a U.S. Army MQ-1C Gray Eagle Extended Range (GE-ER) Unmanned Aircraft System (UAS). The Eaglet flight was jointly funded by GA-ASI and the U.S. Army Combat Capabilities Development (DEVCOM) Army Research Laboratory (ARL) and Aviation & Missile Center (AvMC). "The first flight of the Eaglet was an important milestone for the GA-ASI/U.S. Army team," said GA-ASI President David R. Alexander. "Eaglet is intended to be a low-cost, survivable UAS with the versatility to be launched from a Gray Eagle, rotary-wing aircraft, or ground vehicles. It enables extended reach of sensors and increased lethality while providing survivability for manned aircraft." Eaglet fits into the 'ALE Large' catego
Changes to Vallourec’s management team31.1.2023 18:41:38 CET | Press release
Changes to Vallourec’s management team Meudon, France, 31January 2023 – As part of its "New Vallourec" plan, led by Philippe Guillemot, Chairman and Chief Executive Officer, the Group has developed a three-region organization (North America, South America, and Eastern Hemisphere) to simplify and optimize the operations. This new organization aims at making the Group more efficient and more agile, closer to its customers, and to enhance its industrial performance, through two export bases, Brazil, and Asia. This new organization has led to changes in its Executive Committee, effective February 1, 2023: - Laurent Dubedout is appointed Senior Vice-President, Business Line OCTG, Services and Accessories, Group & Eastern Hemisphere and joins the Executive Committee. - Jacky Massaglia is appointed Senior Vice-President Business Line Project Line Pipe and Process and joins the Executive Committee. - Philippe Carlier, who was SVP Technology and Industry, becomes SVP Group Industry and Eastern
Information on the total number of voting rights and shares31.1.2023 18:00:00 CET | Press release
Ghent, Belgium, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Press release - regulated information Biotalys NV (hereafter the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions (Euronext - BTLS), today announces that 10,000 new shares were issued on 18 January 2023 as a result of the exercise of subscription rights under the Company’s long term incentive plan. In view hereof, and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings (the “Belgian Act”), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows: Share capital: EUR 44,564,320.02Total number of securities carrying voting rights: 30,959,454 (all ordinary shares)Total number of voting rights (= denominator): 30,959,454 (all relating to ordinary shares)Number of rights to subscribe for securities carrying voting rights not yet issued: 2,162,109 “ESOP War